Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. George on Promise of PARP Inhibitors in Prostate Cancer

August 9th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.

Olaparib Improves Radiographic PFS in HRR-Mutant mCRPC

August 7th 2019

Olaparib demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared with enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who harbor a homologous recombination repair gene mutation and have progressed on prior therapy with either androgen receptor inhibitor, meeting the primary endpoint of the phase III PROfound trial.

ADT Associated With Alzheimer Disease, Dementia in Prostate Cancer Survivors

August 6th 2019

Androgen deprivation therapy (ADT) increases the risk of subsequent Alzheimer disease and dementia among men ≥66 years with prostate cancer, according to findings of a large retrospective study that examined the link between ADT treatment and later cognitive dysfunction.

Dr. Stadler on Active Surveillance in Prostate Cancer

August 1st 2019

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Role of PARP Inhibitors in Prostate Cancer

July 31st 2019

Considerations for Genetic Testing in Prostate Cancer

July 31st 2019

Sequencing in Nonmetastatic and Metastatic CRPC

July 31st 2019

Patient Selection for Radium-223 in mCRPC

July 31st 2019

Reducing Risk of Fracture in Metastatic CRPC

July 31st 2019

AR-V7 as a Predictive Biomarker in Metastatic CRPC

July 31st 2019

Frontline Therapy in Newly Diagnosed Metastatic HSPC

July 31st 2019

Historical Perspectives on ADT in Prostate Cancer

July 31st 2019

ASCO 2019: Novel Agents in Metastatic CSPC

July 31st 2019

Expanding Treatment Options for Metastatic CSPC

July 31st 2019

Cardiac Toxicity in Nonmetastatic CRPC

July 31st 2019

Management of Adverse Events in M0 CRPC

July 31st 2019

Practical Advice on Follow-Up for Patients with M0 CRPC

July 31st 2019

Benefits of Newly Approved Drugs for M0 CRPC

July 31st 2019

MFS as a Clinical Endpoint in nmCRPC

July 31st 2019

Imaging Utilized in Diagnosis of CRPC

July 31st 2019